Johnson & Johnson's Covid-19 vaccine protected monkey in single shot



A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19.

"This vaccine led to robust protection against SARS-CoV-2 in rhesus macaques and is now being evaluated in humans," said study researcher Dan H. Barouch from Beth Israel Deaconess Medical Center (BIDMC) in the US.

The vaccine uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus.

Barouch has been working on the development of a Covid-19 vaccine since January when Chinese scientists released the SARS-CoV-2 genome. Read More


Comments

Popular posts from this blog

Invest in smallcase with sebi registered professionals

Teji Mandi Your Ultimate Share Market App for Informed Investing

Unleashing the Potential of Stocks: Crafting a Successful Stock Portfolio